Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.53 |
| ▸ | F7 | P08709 | 10/20 | 0.53 |
| ▸ | F3 | P13726 | 10/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 7/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247707 | 0.89 | F2 (0.60) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL5885589 | 0.85 | F2 (0.59) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7449497 | 0.84 | TPSAB1 (0.57) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7020450 | 0.83 | TPSAB1 (0.54) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7021593 | 0.83 | TPSAB1 (0.53) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7403728 | 0.81 | TPSAB1 (0.49) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7021053 | 0.80 | TPSAB1 (0.51) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7140320 | 0.80 | F2 (0.47) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL7026586 | 0.79 | TPSAB1 (0.50) | F2F7F3PRSS1TPSAB1 | |
| SCHEMBL3247710 | 0.79 | P2RX7 (0.43) | F2F7F3PRSS1TPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| EP-1589029-A2 | Pyrazinone protease inhibitors | Johnson & Johnson Pharmaceutical Research & Development L.L.C. (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1086122-B1 | PYRAZINONE PROTEASE INHIBITORS | JOHNSON & JOHNSON PHARM RES (US) | 2005-08-24 | — | — | EP | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| US-6204263-B1 | THROMBIN INHIBITORS. | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | F2 23/4885F7 98/4885F3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.